Publications by authors named "Moshe Zilberstein"

Claim this Profile
A
A phase 1, open-label study to assess the pharmacokinetics, safety, and tolerability of a single intravenous injection of efanesoctocog alfa in adults with type 2N or type 3 von Willebrand disease.
Sophie Susen, Marc Trossaërt, Moshe Zilberstein, Lara Mamikonian, Elena Santagostino

J Thromb Haemost· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, tolerability, and activity of the active C1s antibody riliprubart in cold agglutinin disease: a phase 1b study.
Shirley D'Sa, Josephine M I Vos, Wilma Barcellini, Marek Wardęcki, Laurent Perrin, Moshe Zilberstein

Blood· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics of recombinant factor VIII in adults with severe hemophilia A: fixed-sequence single-dose study of octocog alfa, rurioctocog alfa pegol, and efanesoctocog alfa.
Toshko Lissitchkov, Annemieke Willemze, Christelle Jan, Moshe Zilberstein, Suresh Katragadda

Res Pract Thromb Haemost· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, pharmacokinetics and target engagement of novel RIPK1 inhibitor SAR443060 (DNL747) for neurodegenerative disorders: Randomized, placebo-controlled, double-blind phase I/Ib studies in healthy subjects and patients.
Maurits F J M Vissers, Jules A A C Heuberger, Geert Jan Groeneveld, Jerome Oude Nijhuis, Peter Paul De Deyn, Moshe Zilberstein

Clin Transl Sci· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sarilumab and adalimumab differential effects on bone remodelling and cardiovascular risk biomarkers, and predictions of treatment outcomes.
Cem Gabay, Gerd R Burmester, Vibeke Strand, Jérôme Msihid, Moshe Zilberstein

Arthritis Res Ther· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of sarilumab pharmacodynamic and predictive markers in patients with inadequate response to TNF inhibition: a biomarker substudy of the phase 3 TARGET study.
Cem Gabay, Jérôme Msihid, Moshe Zilberstein, Caroline Paccard, Yong Lin

RMD Open· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The efficacy and safety of subcutaneous clazakizumab in patients with moderate-to-severe rheumatoid arthritis and an inadequate response to methotrexate: results from a multinational, phase IIb, randomized, double-blind, placebo/active-controlled, dose-ranging study.
Michael E Weinblatt, Philip Mease, Eduardo Mysler, Tsutomu Takeuchi, Edit Drescher, Moshe Zilberstein

Arthritis Rheumatol· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mining the human genome for new health therapies.
Moshe Zilberstein

Fertil Steril· March 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preimplantation genetic diagnosis for a couple with recurrent pregnancy loss and triploidy.
Shalom Bar-Ami, Machelle M Seibel, Kenneth E Pierce, Moshe Zilberstein

Birth Defects Res A Clin Mol Teratol· November 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Becoming parents after 100?
Machelle M Seibel, Moshe Zilberstein, Sharon Seibel

Lancet· March 1994

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis